olafertinib (CK-101) / Fortress, Suzhou NeuPharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
olafertinib (CK-101) / Fortress
CTR20200563: Phase III clinical study of RX518 as first-line treatment for patients with non-small cell lung cancer

Recruiting
3
480
China
olafertinib (CK-101) - Fortress, gefitinib - Generic mfg.
Suzhou Runxin Biotechnology Co., Ltd.
Advanced Non-small Cell Lung Cancer;Oncology
 
 

Download Options